|
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Clinical research trials and Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer. Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer  Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
For Condition: squamous cell lung cancer,adenocarcinoma of the lung,recurrent non-small cell lung cancer,adenosquamous cell lung cancer,large cell lung cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Garden State Cancer Center
Synopsis: RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have relapsed or refractory non-small cell lung cancer.
Details: OBJECTIVES: I. Determine the dose-limiting toxicity and maximum tolerated dose of yttrium Y 90 anti-CEA monoclonal antibody MN-14 in patients with relapsed or refractory non-small cell lung cancer. II. Determine the dosimetric and pharmacokinetic properties of this treatment regimen in the blood, normal organs, and tumors of these patients. III. Determine the stability and complexation with circulating carcinoembryonic antigen of this radioantibody in the plasma of these patients. IV. Determine the antibody response of these patients with this treatment regimen. V. Determine the antitumor effects of this treatment regimen in these patients. PROTOCOL OUTLINE: This is a dose escalation study of yttrium Y 90 anti-CEA monoclonal antibody MN-14 (90Y-hMN-14). Patients undergo pretherapy imaging with indium In 111 anti-CEA monoclonal antibody MN-14 IV over 30-40 minutes on day -7 or -6, followed by external scintigraphy on days -7 or -6 to 0. Patients who show positive localization of at least one documented tumor site receive 90Y-hMN-14 IV over 30-40 minutes on day 0. Cohorts of 3-6 patients receive escalating doses of 90Y-hMN-14 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 2, 4, 8, and 12 weeks; every 3 months for 2 years; and then every 6 months for 3 years. PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically or cytologically confirmed non-small cell lung cancer; Adenocarcinoma, squamous large cell, or mixed cell histology; Patients with nonadenocarcinomatous disease must have evidence of carcinoembryonic antigen (CEA) production or expression documented by one of the following: Serum CEA at least 10 ng/mL; Positive immunohistology of either the primary tumor or a metastasis with CEA-specific monoclonal antibody - Must have received at least one prior regimen of standard chemotherapy and, if indicated, no greater than 6,900 cGy thoracic radiotherapy - Patients with stage IIIA/B unresectable disease who received prior radiotherapy must show evidence of progressive disease (greater than 25% increase in primary tumor or appearance of new lesions) - Patients with stage IIIB or IV disease who received no prior radiotherapy to the primary or index lesion must show evidence of stable or progressive disease by CT scans at least 4 weeks apart - Less than 25% tumor involvement in bone marrow - No known, active brain metastases --Prior/Concurrent Therapy-- - Biologic therapy: No prior stem cell transplantation after high-dose chemotherapy; No concurrent growth factors - Chemotherapy: See Disease Characteristics; See Biologic; At least 4 weeks since prior chemotherapy - Endocrine therapy: Not specified - Radiotherapy: See Disease Characteristics; At least 4 weeks since prior radiotherapy; Prior radiotherapy to less than 30% of red marrow allowed - Surgery: At least 4 weeks since prior major surgery --Patient Characteristics-- - Age: 18 and over - Performance status: Karnofsky 70-100% ECOG 0-2 - Life expectancy: At least 3 months - Hematopoietic: WBC at least 3,000/mm3; Granulocyte count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 2 mg/dL; AST no greater than 2 times upper limit of normal (ULN); No hepatitis B or C; No other serious liver abnormality - Renal: Creatinine no greater than 1.5 times ULN; No urinary incontinence - Cardiovascular: Ejection fraction at least 50% by MUGA - Pulmonary: FEV1 at least 60% DLCO at least 50% - Other: No severe anorexia, nausea, or vomiting; No other significant medical problems; No prisoners; No reactivity to humanized MN-14 (in patients with prior exposure to chimeric or humanized antibody); HIV negative; Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for at least 3 months after study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JackBurton, Study Chair, Garden State Cancer Center
Garden State Cancer Center
Belleville, New Jersey, 07103
United States
Additional Information:
Study ID Numbers: CDR0000068198; CMMI-C-047A-99,NCI-H00-0063
Study Start Date: August 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006458
Other Adenocarcinoma Of The Lung Studies:
1. Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
2. Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
3. Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed
4. Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
5. Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Related Studies:
Other adenocarcinoma of the lung Clinical Trials
Other New Jersey Clinical Trials
Other Belleville Clinical Trials
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
|
|
|
|
|
|
|
|
